Pure Biologics Spólka Akcyjna

Warsaw Stock Exchange PUR.WA

Pure Biologics Spólka Akcyjna Operating Cash Flow for the year ending December 31, 2023: USD -5.90 M

Pure Biologics Spólka Akcyjna Operating Cash Flow is USD -5.90 M for the year ending December 31, 2023, a -48.65% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Pure Biologics Spólka Akcyjna Operating Cash Flow for the year ending December 31, 2022 was USD -3.97 M, a 33.26% change year over year.
Pure Biologics Spólka Akcyjna Operating Cash Flow for the year ending December 31, 2021 was USD -5.95 M, a -1,541.40% change year over year.
Pure Biologics Spólka Akcyjna Operating Cash Flow for the year ending December 31, 2020 was USD -362.24 K, a -125.81% change year over year.
Pure Biologics Spólka Akcyjna Operating Cash Flow for the year ending December 31, 2019 was USD 1.40 M, a 311.36% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Warsaw Stock Exchange: PUR.WA

Pure Biologics Spólka Akcyjna

CEO	Dr. Filip Jelen M.B.A., Ph.D.
IPO Date	Dec. 1, 2018
Location	Poland
Headquarters	ul. Dunska 11
Employees	4
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

Pure Biologics Spólka Akcyjna, a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use. It also engages in the development of non-systemic therapies for use in treating patients suffering from neurological autoimmune disorders, including neuromyelitis optica and myasthenia gravis. Pure Biologics Spólka Akcyjna was founded in 2010 and is headquartered in Wroclaw, Poland.

Key trends

Past 5 years